InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,731.10
(
1.34%
)
Post# of 251707
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

pcrutch

Send PM Follow Ignore
Followers 69
Posts 2711
Boards Moderated 0
Alias Born 02/25/2010

pcrutch

Re: mcbio post# 177328

Monday, 04/28/2014 12:16:56 AM

Monday, April 28, 2014 12:16:56 AM

Post# of 251707
Wonder what effect NVS will have on them, Ph3 data in second half of this year on PKC412 in FLT3+ AML. Could present a challenge to AMBI trial enrollment and future sales competition.

http://clinicaltrials.gov/ct2/show/NCT00651261?term=Midostaurin&rank=14

Interesting info. Long road ahead for AMBI - NVS had to screen 3200 patients to get 700 randomized.
http://www.iom.edu/~/media/Files/Activity%20Files/Disease/NCPF/2013-FEB-11/Capdeville.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up